My watch list
my.bionity.com  
Login  

Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

GBI Research, a leading business intelligence provider, has released its latest research “Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development”, which provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Research’s team of experts.

Report Highlights
GBI Research, the leading business intelligence provider, has released its latest research “Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development”. It provides a comprehensive analysis of the late stage pipeline molecules in 14 key indications from nine major therapy areas. The report provides in-depth coverage of the pipeline activity in the major indications, giving a wide view on the changing focus of the therapeutic landscape. Each chapter deals exhaustively with one indication, giving: an overview of the opportunity and unmet need in the market; a strategic pipeline assessment that covered the distribution of the pipeline according to their mechanism of action and class of drug, whether first-in-class, me-too, or generic or product extension; and a comparative analysis of key late stage pipeline molecules based on the major characteristics of targeted unmet need, mechanism of action, efficacy and safety. Furthermore, the report provides profiles of the promising drugs under clinical development.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Oncology, Metabolic Disorders and CNS Command Robust Late Stage Pipeline

The therapy areas that command the largest number of molecules in the late stage pipeline are – oncology, metabolic disorders and central nervous system disorders. Oncology accounts for the majority of pipeline activity, with 37% of the entire pipeline. The focus on oncology to develop novel anti-cancer drugs is driven partly by patients’ constant need to switch treatments due to the side effects of heavy chemotherapy. Several companies, including Pfizer, Sanofi-aventis, Bristol-Myers Squibb (BMS) and Amgen are developing protein-based therapeutics since they do not carry the adverse effects associated with intense chemotherapy.

Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, by Therapy Area, 2011

Source: GBI Research, Company Websites, Clinicaltrials.gov

Kinase Inhibitors – Most Important First-in-class Drug

Tyrosine kinase inhibitors are one of the most prominent developing classes of drug undergoing Phase II and Phase III evaluation; they account for approximately 40% of the Phase III promising molecules in oncology, followed by therapeutic vaccines, mammalian target of rapamycin (mTOR) inhibitors and Cytochrome P450 inhibitors among others. Specific inhibitors of tyrosine kinases are extremely advantageous and provide more promise against monoclonal antibodies since they are targeted at the tyrosine kinase activity of receptor tyrosine kinase (RTK). Inhibition of the activity of receptor and other tyrosine kinases represents a rational strategy to stop the functions of cells that rely on these pathways for survival. Non-cancer applications of kinase inhibitors are seen across diseases such as autoimmune diseases, restenosis, diabetes and other disorders.

Type 2 Diabetes Pipeline Inundated With Me-too Drugs

Type 2 diabetes has the highest number of me-too drugs among all the indications analyzed with 174 such products in the pipeline accounting for 69% of the entire pipeline. Me-too drugs largely duplicate the action of existing drugs and diminish the incentives for innovation in pioneering drugs without adding therapeutic value. However, the more differentiated me-too drugs are from pioneering drugs, the greater their potential benefits. In the case of type 2 diabetes, these me-too drugs are anticipated to provide better efficacy and safety profiles. Several glitazones and glucagon-like peptide-1 (GLP-1) analogues are me-too drugs in the pipeline.

Pharmacy / Drugs   Market study
Year:   2011
Publisher:   GBI Research
Price:   3,500.00€
More about GBI Research
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE